Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Eosinophilic Granulomatosis With Polyangiitis Treatment Market Size Shifted, And What Is the Outlook Through 2034?
There has been considerable growth in the eosinophilic granulomatosis with polyangiitis treatment market in recent times. Expect to see an increase from $1.28 billion in 2024 to $1.41 billion in 2025, a compound annual growth rate (CAGR) of 9.8%. Factors such as the increasing prevalence of Churg Strauss syndrome, the rising demand for efficient treatment methods, accelerating research and development activities, an aging populace, and heightened patient awareness have all contributed to the historical growth period.
In the forthcoming years, the market for eosinophilic granulomatosis with polyangiitis treatment is anticipated to witness robust growth. The projections indicate an expansion to a value of $2.04 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.7%. The growth predicted for the forecast period could be attributed to factors like growing emphasis on biologics and targeted therapies, an escalation in clinical trial activities, increasing patient advocacy movements, a rising focus on precision and personalized therapy, and an escalating incidence of asthma among the aged population. The period also sees major trends like technological advancements, progress in therapeutic agents and biologics, personalized medicine strategies, alliances between healthcare providers and pharmaceutical companies, and enhancements in diagnostic techniques.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23392&type=smp
Which Factors and External Forces Are Driving Demand in the Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
The escalating instances of asthma prevalent amongst the elderly population are expected to drive the expansion of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market. Asthma, a condition typified by inflamed, constricted airways resulting in difficulty in breathing, is increasingly common among the aging due to dwindling lung functionality. As the lungs lose their elasticity and respiratory muscles weaken, it exacerbates breathing problems, thus the elderly become more prone to inflammation and respiratory issues. This surge in asthma incidents among senior citizens, results in an increase in screenings for associated conditions like eosinophilic granulomatosis with polyangiitis, a condition that usually commences with asthma, fueling the demand for its treatment. For instance, the Global Initiative for Asthma, an American medical organization, mentioned in 2024 that asthma is a widespread chronic non-transmissible disease, affecting upwards of 260 million individuals globally and causing over 450,000 deaths per year. Consequently, the growing prevalence of asthma amongst the aging populace significantly contributes to the expansion of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market.
Which Segments in the Eosinophilic Granulomatosis With Polyangiitis Treatment Offer the Most Growth?
The eosinophilic granulomatosis with polyangiitis treatmentmarket covered in this report is segmented –
1) By Drug Class: Steroids; Immunosuppressant; Biologics; Immune Globulins
2) By Route Of Administration: Oral; Intravenous; Intramuscular
3) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Drug Stores; Retail Pharmacies
4) By End User: Hospitals; Clinics; Home Healthcare
Subsegments:
1) By Steroids: Glucocorticoids; Mineralocorticoids
2) By Immunosuppressants: Calcineurin Inhibitors; Antimetabolites; Alkylating Agents
3) By Biologics: Interleukin Inhibitors; Monoclonal Antibodies; TNF-alpha Inhibitors
4) By Immune Globulins: Intravenous Immunoglobulin (IVIG); Subcutaneous Immunoglobulin (SCIG)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23392&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Eosinophilic Granulomatosis With Polyangiitis Treatment Market?# Market?
North America was the largest region in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic granulomatosis with polyangiitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive theEosinophilic Granulomatosis With Polyangiitis Treatment Market’s Growth?
Leading firms in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market are performing clinical tests to evaluate the safety and efficiency of new and currently available treatments. These clinical studies are designed to broaden treatment possibilities, obtain regulatory authorization, and enhance patient healthcare. For example, in September 2024, the UK-based pharmaceutical and biotech firm, AstraZeneca, disclosed successful outcomes from the MANDARA Phase III trial. The research found that Fasenra (benralizumab) is proficient in provoking remission in EGPA patients. The trial concluded that benralizumab achieved remission rates on par with those of mepolizumab, while also lessening the requirement for oral glucocorticoids. This progress signals a significant shift toward more specific and less steroid-reliant treatment strategies for eosinophilic granulomatosis with polyangiitis.
View the full report here:
What Are the Key Elements That Define the Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
Eosinophilic granulomatosis with polyangiitis (EGPA) treatment refers to medical approaches used to manage this rare autoimmune disease, which causes inflammation of small blood vessels. The treatment focuses on reducing inflammation, controlling symptoms, and preventing disease progression.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23392
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model